---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-127218"
form_type: "8-K/A"
ticker: "HURA"
cik: "0001498382"
company_name: "TuHURA Biosciences, Inc./NV"
filed_at: "2024-11-14T23:59:59+00:00"
generated_at: "2026-05-30T00:25:53.222585+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# TuHURA posts $15.7M net loss through Q3 2024; convertible debt rises to $24.4M

## Summary
- Net loss of $15.7M for nine months ended Sep 30, 2024 vs $26.6M prior year (prior year included $16.2M IPR&D charge).
- Operating loss of $12.0M vs $27.1M YoY; R&D spend up to $9.4M from $7.5M.
- Cash position $19.6M at Sep 30, 2024, up from $3.7M year-end 2023 after $28.6M convertible note issuance.
- Convertible notes payable net of discount total $24.4M; derivative liability of $2.9M recorded.
- Stockholders' deficit worsened to $(2.8M) from $(1.6M); closed merger with Kintara on Oct 18, 2024.

## SEC filing metadata
- accession: 0000950170-24-127218
- form_type: 8-K/A
- ticker: HURA
- cik: 0001498382
- company_name: TuHURA Biosciences, Inc./NV
- filed_at: 2024-11-14T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1498382/000095017024127218/0000950170-24-127218-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1498382/000095017024127218/hura-20241018.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-127218
- JSON: https://secwatch.observer/filing/0000950170-24-127218.json
- Plain text: https://secwatch.observer/filing/0000950170-24-127218.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.